Zinc Supplementation on Very Low Birth Weight Infant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

364 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-20

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Premature birth is a major cause of neonatal death in addition to neonatal asphyxia and infections.

Early in life, premature babies must get aggressive nutrition so that there is no extrauterine growth restriction (EUGR) in the Intrauterine Growth Restriction (IUGR) group compared to the non-IUGR group.

Other factors that also play a role are long episodes of fasting, the fulfillment of nutrition (macro and micronutrients) from the start, time to start breastfeeding (ASI), duration of parenteral total administration, the incidence of respiratory distress syndrome and incidence of necrotizing enterocolitis.

Zinc is one of the micronutrients which is very risky for deficiency in premature babies.

Babies with zinc deficiency experience growth disorders as much as 67%. In India, infants who received zinc supplementation increased after being given 10 days of zinc supplementation and lower mortality rates in the group with supplementation. Very low birth weight babies and bronchopulmonary dysplasia who received zinc supplementation during the week showed good clinical progress and the growth rate also increased.

The investigators believe this study has the potential for decreasing infant mortality from its current level and can be a growth indicator for preterm babies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of β-Carotene, Vitamin D3 and Zinc on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates

NCT03366584

Hyaline Membrane Disease Necrotizing Enterocolitis of Newborn

UNKNOWN PHASE4

Sodium Supplementation and Growth in Very Low Birth Weight Infants

NCT01795638

Extreme Immaturity

TERMINATED PHASE4

Bovine Colostrum in Prevention of Sepsis and Retinopathy of Prematurity

NCT05438680

Preterm

COMPLETED NA

Iron Supplementation and Neurodevelopmental Outcome in ELGANs

NCT04691843

Iron-deficiency

COMPLETED PHASE3

IgM-Enriched Immunoglobulin for Neonatal Sepsis

NCT04041765

Neonatal Sepsis, Early-Onset Very Low Birth Weight Infant Inflammation +1 more

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Double-blind randomized controlled clinical trial in preterm infants (28 - 32 weeks) who are newborn or less than 3 days old who are admitted to the perinatology room.

Infant in the intervention group was given elemental zinc supplementation once daily orally compared to placebo in the control group, at 3 days of age until the patient returned home or a maximum of 40 weeks' gestation.

The intervention group was given 10 mg elemental zinc once daily orally compared to placebo in the control group, at 3 days of age and received oral nutrition\> 20cc / kg/ day, continued during treatment until the patient returned home or a maximum of 40 weeks' gestation.

Monitored infant development indicators, measured once a week. Monitoring of the incidence of infection in late-onset infants in clinical and laboratory settings according to the existing hospital settings.

The monitoring of NEC events in all research subjects was carried out. Screening ROP at the age of 3 weeks and/or when the baby is going home. The participants were observed to be allowed to go home or a maximum of 40 weeks' gestation if they were still being treated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Early-Onset Sepses, Neonatal Periventricular Haemorrhage Neonatal Bronchopulmonary Dysplasia Retinopathy of Prematurity Enterocolitis, Necrotizing Small for Gestational Age Infant

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Double-blind randomized controlled clinical trial in preterm infants (28 - 32 weeks) who are newborn or less than 3 days old who are admitted to the perinatology room. There were two research groups, namely the treatment group (the group that received zinc supplementation) and the control group (the group that received the placebo). In both groups the differences in growth indicators (body weight, body length, and head circumference) will be evaluated, the incidence of morbidity (sepsis, necrotizing enterocolitis, retinopathy of prematurity, intraventricular hemorrhage and bronchopulmonary dysplasia).

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Randomization is carried out by research assistants, then making sequential numbers with closed envelopes that have been prepared. The results of the randomization are only known by research assistants. At the age of 3 days or priming\> 20cc / kg body weight/day, the research assistant will give a bottle of medicine containing zinc/placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse. The researcher monitors all patients who are sampled without knowing which group is the test and which group is the control.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group

Participants who receive the intervention.

Group Type ACTIVE_COMPARATOR

Zinc Sulfate

Intervention Type DRUG

At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.

Control Group

Participants who receive the placebo.

Group Type PLACEBO_COMPARATOR

Placebos

Intervention Type DRUG

At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Zinc Sulfate

At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing zinc (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.

Intervention Type DRUG

Placebos

At the age of 3 days or priming\> 20cc / kg body weight/day the research assistant will give a bottle of medicine containing placebo (according to the results of randomization) without knowing the contents either by the doctor or the room nurse.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Preterm (gestational age of 28 - 32 weeks)
* Newborns with a ratio of body weight and gestational age: Small for Gestational Age or Large for Gestational Age
* Get parental approval to be included in the study by signing an informed consent

Exclusion Criteria

* Newborns with severe congenital abnormalities
* Newborns with digestive tract abnormalities: partial, total obstruction or gastrointestinal atresia
* Newborns with unstable hemodynamic conditions that will affect the survival rate
* Mothers who consume alcohol regularly (≧ 2x a month) during pregnancy
* Newborns with early-onset sepsis

Maximum Eligible Age

3 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes